
Arvinas’ prostate cancer treatment shows hints of signal — but how many patients will it work for?
Arvinas released interim results Thursday morning on one of its protein degrader drugs for prostate cancer ahead of a fireside chat at the Jefferies investor conference.
The droplet of efficacy data suggest Arvinas’ drug can help reduce levels of a biomarker elevated in prostate cancer, and potentially shrink tumors, but the drug was designed for a specific (and small) subset of patients.
In four patients with metastatic castration-resistant prostate cancer (mCRPC) evaluated for whether their tumors responded to Arvinas’ treatment ARV-766, which is an androgen receptor degrader, one had a confirmed partial response and one had an unconfirmed partial response. And in 12 patients evaluated for PSA levels, a common marker used to assess prostate cancer, five saw their PSA levels drop by 50%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.